Aripiprazole and risperidone in treatment of the patients with schizophrenia: a randomly clinical trial

Objective To investigate the clinical efficacy and safety of aripiprazole and risperidone in treatment of the patients with acute schizophrenia.Methods In the 6-week randomly controlled trial,197patients with acute schizophrenia were treated with aripiprazole or risporidone.The efficacy was assessed with the Positive and Negative Symptoms Scale(PANSS),and side effects with the Treatment Emergent Symptoms Scale and the changes of biochemical index and electrocardiogram at baseline and after 1,2,4,6-week treatment.Results In aripiprazole group,the positive,psychopathlolgical subscale scores and total score of PANSS were significantly decreased(P＜0.05)after 1 week treatment.After 6-week aripiprazole treatment.the PANSS scores(positive:12.5 ±6.3,negative:14.8 ±7.6,total:54.7 ±21.3)were significantly reduced in comparison with the baseline(positive:22.1±6.9,negative:21.8 ±8.6,total:85.1±18.6)(P＜0.01),with better efficacy than risperidone.In this 6-week study,weisht gain and abnormalities in electrocardiogram were not found in aripiprazole treatment group.Conclusion Aripiprazole is effective and safe in treatment of the patients with acute schizophrenia. Key words: Schizophrenia; Treatment outcom; Risporidone;  Aripiprazole